192 related articles for article (PubMed ID: 14633081)
1. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder.
Kakizaki H; Ameda K; Kobayashi S; Tanaka H; Shibata T; Koyanagi T
Int J Urol; 2003 Nov; 10(11):576-81. PubMed ID: 14633081
[TBL] [Abstract][Full Text] [Related]
2. [Urodynamic evaluation of alpha-1 blocker tamsulosin on benign prostatic hyperplasia using pressure-flow study].
Miyatake R; Park YC; Koike H; Ohnishi N; Sugiyama T; Kurita T; Esa A; Kiwamoto H
Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1048-55. PubMed ID: 8831212
[TBL] [Abstract][Full Text] [Related]
3. Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children.
Vanderbrink BA; Gitlin J; Toro S; Palmer LS
J Urol; 2009 Feb; 181(2):817-22; discussion 822. PubMed ID: 19110267
[TBL] [Abstract][Full Text] [Related]
4. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand.
Arnold EP
BJU Int; 2001 Jan; 87(1):24-30. PubMed ID: 11121988
[TBL] [Abstract][Full Text] [Related]
5. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and tamsulosin, an alpha1-adrenoceptor antagonist, and their synergistic effects on the urodynamic characteristics in a guinea-pig model of functional bladder outlet obstruction.
Nagabukuro H; Hashimoto T; Iwata M; Doi T
BJU Int; 2005 May; 95(7):1071-6. PubMed ID: 15839935
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of tamsulosin in treating women with voiding difficulty.
Chang SJ; Chiang IN; Yu HJ
Int J Urol; 2008 Oct; 15(11):981-5. PubMed ID: 18721208
[TBL] [Abstract][Full Text] [Related]
8. Neurogenic failures of the external urethral sphincter closure and relaxation; a videourodynamic study.
Sakakibara R; Hattori T; Uchiyama T; Yamanishi T; Ito H; Ito K
Auton Neurosci; 2001 Jan; 86(3):208-15. PubMed ID: 11270099
[TBL] [Abstract][Full Text] [Related]
9. α1-Blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a prospective randomized study.
Minardi D; Pellegrinelli F; Conti A; Fontana D; Mattia M; Milanese G; Muzzonigro G
Int J Urol; 2015 Jan; 22(1):115-21. PubMed ID: 25141907
[TBL] [Abstract][Full Text] [Related]
10. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
Utomo E; Groen J; Blok BF
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004927. PubMed ID: 24859260
[TBL] [Abstract][Full Text] [Related]
11. Normal preoperative urodynamic testing does not predict voiding dysfunction after Burch colposuspension versus pubovaginal sling.
Lemack GE; Krauss S; Litman H; FitzGerald MP; Chai T; Nager C; Sirls L; Zyczynski H; Baker J; Lloyd K; Steers WD;
J Urol; 2008 Nov; 180(5):2076-80. PubMed ID: 18804239
[TBL] [Abstract][Full Text] [Related]
12. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
Cervenakov I; Fillo J
Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
[TBL] [Abstract][Full Text] [Related]
13. Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms.
Turner CD; Kuznetsov D; Contreras BA; Gerber GS
Tech Urol; 1998 Sep; 4(3):136-40. PubMed ID: 9800891
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study.
Lee KS; Han DH; Lee YS; Choo MS; Yoo TK; Park HJ; Yoon H; Jeong H; Lee SJ; Kim H; Park WH
J Korean Med Sci; 2010 Jan; 25(1):117-22. PubMed ID: 20052356
[TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study].
Koyanagi T; Togashi M; Maru A; Orikasa S; Soma F; Shimazaki J; Yasuda K; Aso Y; Honma Y; Miyake K
Hinyokika Kiyo; 1990 Oct; 36(10):1233-52. PubMed ID: 1979900
[TBL] [Abstract][Full Text] [Related]
16. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
17. Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms.
Kaplan SA; Stifelman M; Avillo C; Reis RB; Te AE
Eur Urol; 2000 Mar; 37(3):314-7. PubMed ID: 10720858
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
[TBL] [Abstract][Full Text] [Related]
19. Urodynamic patterns of normal male micturition: influence of water consumption on urine production and detrusor function.
Schmidt F; Shin P; Jorgensen TM; Djurhuus JC; Constantinou CE
J Urol; 2002 Oct; 168(4 Pt 1):1458-63. PubMed ID: 12352417
[TBL] [Abstract][Full Text] [Related]
20. [Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinary bladder in patients with multiple sclerosis].
Stankovich EIu; Borisov VV; Demina TL
Urologiia; 2004; (4):48-51. PubMed ID: 15457955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
